| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester manufacturers
|
| | Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester Basic information |
| Product Name: | Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester | | Synonyms: | Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester;Menin-MLL inhibitor 20,MRN73473;Menin-MLL inhibitor 20;Epigenetic Reader Domain,mixed-lineage,MeninMLL inhibitor 20,irreversible,leukemia,MLL,Inhibitor,antitumor,Menin MLL inhibitor 20,inhibit,Menin,Menin-MLL inhibitor 20;(R)-4-[[3-(Boc-amino)-1-piperidyl]methyl]-N-[4-(4-morpholino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]pyridine-2-carboxamide;tert-butyl N-[(3R)-1-{[2-({4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}carbamoyl)pyridin-4-yl]methyl}piperidin-3-yl]carbamate;Menin-MLL inhibitor 20, 10 mM in DMSO;(R)-tert-Butyl (1-((2-((4-(4-morpholino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)carbamoyl)pyridin-4-yl)methyl)piperidin-3-yl)carbamate | | CAS: | 2448173-47-3 | | MF: | C33H40N8O4 | | MW: | 612.72 | | EINECS: | | | Product Categories: | | | Mol File: | 2448173-47-3.mol | ![Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester Structure](CAS/20210305/GIF/2448173-47-3.gif) |
| | Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 33.33 mg/mL (54.40 mM; ultrasonic and warming and heat to 60°C) | | form | Solid | | pka | 11.80±0.70(Predicted) | | color | Light yellow to yellow |
| | Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester Usage And Synthesis |
| Uses | Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, Intermediate 6)[1]. | | Biological Activity | Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6)[1].
The Histone-lysine N-methyltransferase 2 (KMT2) family of proteins, which currently consists of at least 5 members, methylate ly sine 4 on the histone H3 tails at important regulatory regions in the genome and thereby impart crucial functions through the modulation of chromatin structures and DNA accessibility. These enzymes are known to play an important role in the regulation of gene expression during early development and hematopoiesis. The human KMT2 family was initially named the mixed-lineage leukaemia (MLL) family, owing to the role of the first-found member in this disease[1]. | | References | [1]. Thomas Butler, et al. Irreversible inhibitors of menin-mll interaction. WO2020142557A1. |
| | Carbamic acid, N-[(3R)-1-[[2-[[[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]amino]carbonyl]-4-pyridinyl]methyl]-3-piperidinyl]-, 1,1-dimethylethyl ester Preparation Products And Raw materials |
|